Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX37 plus chemotherapy versus pembrolizumab plus chemotherapy as first-line treatment for advanced non-small cell lung cancer
CTR20263375Phase 2Active
- Sponsor
- Henlius Ruilin
- Start
- Oct 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of HLX37 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Henlius Ruilin. Primary endpoints: Progression-free survival by blinded independent central review and Objective response rate by blinded independent central review. Started Oct 2026; status: active.
02
Drugs
HLX37
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20263375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263375.